KLAVA

KLAVA was founded with a clear mission: to improve access to evidence-based care for individuals with addictive disorders. Stigma and discrimination surrounding these conditions frequently delay access to treatment, leading to gaps in medical care and suboptimal outcomes. In collaboration with the Addiction Medicine Department at AP-HP Paul Brousse, the leading addiction research center in Europe, KLAVA is dedicated to advancing equitable access to high-quality care for patients affected by substance use disorders. KLAVA has concentrated its research efforts on tobacco dependence by developing Quitoxil®, a digital therapeutic accessible via smartphone, designed to assist individuals in reducing or stopping tobacco use. The therapeutic program incorporates clinically validated cognitive and behavioral therapies, providing patients with tools to identify the underlying mechanisms driving their addiction and adopt evidence-based strategies to facilitate cessation. In 2024, Quitoxil® became the first French digital therapeutic for addiction to be distributed in community pharmacies. With thousands of downloads, KLAVA is establishing itself as a pioneer in the field of digital therapeutics for addiction medicine and as a European leader in this domain. Over the next 12 months, the company intends to expand its scope to address other addiction-related conditions, including sugar addiction.